1 not yet recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Elevated Inflammatory Markers: new trials by email Literature Review of Elevated Inflammatory Markers trials Research Report on Elevated Inflammatory Markers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-30 |
Carcinoma, Non-Small-Cell Lung (1)
Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Carboplatin (1) · Pemetrexed (1) · pembrolizumab (1) · taxane (1) · tocilizumab (1)
VA Office of Research and Development (1)
United States (1)